[{"id":"c_e53d2004","claim_text":"DPP4i + Met demonstrated a non-significant lower incidence of CV events in comparison to TZD + Met and SU + Met.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_94d86a95","claim_text":"The study used the Korean National Health Insurance Service database from December 1, 2008, to December 31, 2013.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_31bc160e","claim_text":"The combination of DPP4i + Met revealed a comparable mean reduction in HbA1c levels to the glinides (Gli) + Met combination.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_24e83ac3","claim_text":"The study found no significant increased risk of total CVDs in the DPP-4 inhibitors group compared to the glimepiride group.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_e4182728","claim_text":"DPP4i + Met had a greater mean HbA1c reduction compared to sulfonylureas (SU) + Met and thiazolidinedione (TZD) + Met.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_91f70b24","claim_text":"Patients with a history of visit for CVDs had a decreased risk of hospitalization for CVDs in the DPP-4 inhibitors group compared to the glimepiride group.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_215a5f0a","claim_text":"The combination of DPP4i + Met was efficacious and had a well-tolerated safety profile compared with other traditional OADs.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_66678084","claim_text":"Patients with more than 2.5 years of type 2 diabetes had a decreased risk of hospitalization for CVDs in the DPP-4 inhibitors group compared to the glimepiride group.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_7c089596","claim_text":"Sixty-two trials were included in the analysis for this systematic literature review and network meta-analysis.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_6c9475d1","claim_text":"DPP-4 inhibitors did not increase cardiovascular risk regardless of CVD history and diabetes duration.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_42102eb2","claim_text":"Alogliptin showed a statistically significant benefit in monotherapy compared to placebo.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_bdd7b752","claim_text":"Alogliptin had the highest rating among DPP-4 inhibitors for all subgroups based on SUCRA.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_b3caeaed","claim_text":"The study included 38 randomized clinical trials (RCTs) analyzing DPP-4 inhibitors and their combination with metformin.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_acaa79a5","claim_text":"Alogliptin was found to be superior in monotherapy compared to other DPP-4 inhibitors, including combination with metformin.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_c7200d40","claim_text":"The study's endpoint was the percentage of patients achieving target HbA1c level.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_03413326","claim_text":"The United States led in publication output for DPP-4 inhibitors and cardiovascular outcomes studies.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_367b72c3","claim_text":"Harvard University and the University of Toronto were identified as leading institutions in DPP-4 inhibitor research.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_6d8c87d2","claim_text":"The most influential journals for DPP-4 inhibitors and cardiovascular outcomes studies are Cardiovascular Diabetology and Diabetes Obesity & Metabolism.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_8b128932","claim_text":"Darren K. McGuire was the most prolific author in DPP-4 inhibitor research studies.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_4ff196d2","claim_text":"Heart failure is a frequently occurring keyword in DPP-4 inhibitor and cardiovascular outcomes studies, indicating a strong focus on cardiovascular safety.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_52cef549","claim_text":"DPP-4 inhibitors can reduce daily insulin requirements, especially for patients with a BMI < 25 kg/m² and diabetes duration < 3 years.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_ce3ed1cd","claim_text":"DPP-4 inhibitors can reduce postprandial blood glucose, especially for patients with a BMI < 25 kg/m² and diabetes duration < 3 years.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_9e003ed5","claim_text":"DPP-4 inhibitors may transiently enhance β-cell function in patients with T1DM.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_6f329de5","claim_text":"The efficacy of DPP-4 inhibitors as adjunct therapy for T1DM is not sustained over time, resulting in only a transient improvement in HbA1c.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_5be6eb4e","claim_text":"DPP-4 inhibitors are considered safe for use as adjunct therapy to insulin in patients with T1DM, based on the safety outcomes observed in this study.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_b987fd4c","claim_text":"DPP-4 inhibitors have emerged as a popular class of glucose-lowering agents.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_96fc9c11","claim_text":"The impact of DPP-4 inhibitors on heart failure outcomes in patients with diabetes remains contentious, with conflicting evidence from clinical trials and observational studies.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_a1888ac9","claim_text":"Clinical trials such as SAVOR-TIMI 53, EXAMINE, and TECOS are evaluated to provide a comprehensive analysis of DPP-4 inhibitors' effects.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_e9591f18","claim_text":"Some trials suggest an increased risk of HF hospitalizations with specific DPP-4 inhibitors (e.g., saxagliptin), while others report neutral effects.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_488edf29","claim_text":"Discrepancies in outcomes related to patient demographics, HF phenotype, and comorbid conditions influence DPP-4 inhibitors' risk–benefit profile.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_48280856","claim_text":"Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i), Dipeptyl Peptidase-4 inhibitors (DPP-4i) and Glucagon-Like Peptide-1 agonists (GLP-1a) effectively reduce HbA1c levels.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_315e44d2","claim_text":"Their long-term cardiovascular effects have been tested against placebo, but the comparative efficacy of individual drug types is unclear.","claim_type":"opinion","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_5e97e1b8","claim_text":"A network meta-analysis was conducted to compare the efficacy of SGLT2i, DPP-4i and GLP-1a for reducing cardiovascular outcomes.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_f4799c40","claim_text":"Empagliflozin and liraglutide reduced cardiovascular mortality compared to control (RR 0.63; 95% CI 0.51-0.79; P < 0.001).","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_50094495","claim_text":"This study provides evidence to support clinical decisions in treatment of type 2 diabetes.","claim_type":"opinion","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_63dca6d2","claim_text":"Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) assessed the cardiovascular safety of sitagliptin versus placebo.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_3b6f21a8","claim_text":"The TECOS trial found that sitagliptin is noninferior to placebo in terms of cardiovascular outcomes for patients with type 2 diabetes and CV disease.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_4caa5bf3","claim_text":"Merck & Co., Inc., was the Sponsor of the TECOS trial.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_d4350949","claim_text":"The TIMI Study Group re-adjudicated a prespecified set of originally adjudicated events based on feedback from the FDA for TECOS.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_f41bdc82","claim_text":"The re-adjudication was conducted to reassess the cardiovascular safety of sitagliptin based on feedback from FDA.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_7e81dc25","claim_text":"DPP-4 inhibitors improved the pathogenesis of type 1 diabetes mellitus (T1DM) in preclinical trials.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_18f8d6ac","claim_text":"The additional use of DPP-4 inhibitors resulted in a greater decrease in glycated hemoglobin A1c (HbA1c) levels compared to insulin monotherapy.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_8bcd2c6c","claim_text":"DPP-4 inhibitors showed a small decrease in postprandial glucose or insulin consumption.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_9038afc2","claim_text":"Meta-analysis pooled data from 5 randomized controlled trials.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_acf7f1b2","claim_text":"Existing studies do not strongly support the positive effects of DPP-4 inhibitors in clinical practice.","claim_type":"opinion","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_3606cdd3","claim_text":"SGLT2 inhibitors reduce HbA1c levels significantly more than other treatments.","claim_type":"opinion","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_70561ca9","claim_text":"Metformin is a first-line therapy for T2DM due to its safety, efficacy, and affordability.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_b3fc60f6","claim_text":"DPP-4 inhibitors are weight-neutral and well-tolerated compared to other treatments.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_2b253031","claim_text":"SGLT2 inhibitors provide additional cardiovascular benefits, reducing major adverse cardiovascular events (MACE) and chronic kidney disease progression.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_08aa3744","claim_text":"Insulin is the most potent glucose-lowering agent but carries a higher risk of hypoglycemia and weight gain compared to other treatments.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_fc667104","claim_text":"The model was developed using longitudinal data from 11,234 patients (10 linagliptin, 15 sitagliptin trials).","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_b2d122f2","claim_text":"The model adequately described the observations.","claim_type":"opinion","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_cd972407","claim_text":"Simulations showed both linagliptin 5 mg and sitagliptin 100 mg reduced HbA1c by 0.81% (placebo-adjusted) at week 24.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_1edce0b2","claim_text":"The final model described HbA1c levels as function of time, dose, baseline HbA1c, washout status/duration and ethnicity.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_eafd5cae","claim_text":"This study demonstrates the use of longitudinal MBMA in the field of diabetes treatment.","claim_type":"opinion","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_950b7eb1","claim_text":"Grace period was not reported in 5 (35.7%) studies and ranged from 0 days to 180 days when reported.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_5126e05c","claim_text":"Carry-over was not reported in 10 studies (71.4%).","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_16d86fee","claim_text":"Lag effect was not reported in nine (71.4%) studies and ranged from 0 days to 180 days when reported.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_0fcdb043","claim_text":"No studies conducted sensitivity analyses examining the effects of these assumptions on study findings.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_9abcea9c","claim_text":"Predominant biases were inadequate follow-up time, comparability of cohorts, prevalent use, and lag time bias.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_68777359","claim_text":"Eighteen RCTs involving 6,493 patients with an average follow-up of 32 weeks were identified and analyzed.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_e73edc2a","claim_text":"DPP-4i plus insulin showed greater reduction in HbA1c than insulin alone (WMD -0.52%, 95% CI -0.61 to -0.43; P < 0.00001).","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_e5445730","claim_text":"This updated systematic review and meta-analysis aimed to evaluate the effect of DPP-4i in combination with insulin on HbA1c in T2DM patients.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_d880f8bc","claim_text":"The primary endpoint was the absolute change of HbA1c from baseline.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_c93eb102","claim_text":"DPP-4i plus insulin can significantly lower HbA1c levels in T2DM patients compared to use of insulin alone.","claim_type":"prediction","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_357a7417","claim_text":"The study was conducted using the National Health Insurance Research Database.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_f7626a95","claim_text":"Patients with type 2 diabetes and advanced chronic kidney disease were identified during the period from 2011 to 2015.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_05337f3c","claim_text":"The primary outcome of the study was the composite renal outcome.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_5d6db745","claim_text":"DPP4is reduced the risks of hospitalized hypoglycemia and all-cause death compared to sulfonylureas.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_0b254636","claim_text":"The study concluded that DPP4is may be preferred for patients with type 2 diabetes and advanced chronic kidney disease, and regular monitoring of cardiac function is crucial.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_ea0d58aa","claim_text":"SGLT-2 inhibitors achieved greater reductions in HbA1c compared to DPP-4 inhibitors.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_cd6014c6","claim_text":"SGLT-2 inhibitors showed greater reductions in body weight compared to DPP-4 inhibitors.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_5d8af322","claim_text":"In North America and Europe, SGLT-2 inhibitors had significant reductions in HbA1c and FPG levels compared to Asia.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_7f87b57f","claim_text":"SGLT-2 inhibitors are associated with an increased incidence of genital infections (OR 4.49; 95% CI: 2.96, 6.83; p=0.000).","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_49dd9cbb","claim_text":"SGLT-2 inhibitors are associated with a higher incidence of pollakiuria (OR 2.24; 95% CI: 1.05, 4.79; p=0.037).","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_07fb6821","claim_text":"Ertugliflozin is a new sodium-glucose co-transporter-2 inhibitor (SGLT2i) for the treatment of type 2 diabetes mellitus.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_b3505ddb","claim_text":"The primary objective was to indirectly compare ertugliflozin to other SGLT2is in patient populations with inadequately controlled glycated hemoglobin (HbA1c > 7.0%) and previously treated with either diet/exercise, metformin alone or metformin plus a dipeptidyl peptidase-4 inhibitor (DPP4i).","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_1afc8e7d","claim_text":"Bayesian network meta-analysis was used to synthesize evidence.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_90a99231","claim_text":"In patients uncontrolled on diet/exercise, the efficacy of ertugliflozin 5 mg monotherapy was not significantly different from that of other low-dose SGLT2is in terms of HbA1c reduction.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_00319d8a","claim_text":"As add-on therapy to metformin, ertugliflozin 5 mg was more effective in lowering HbA1c than dapagliflozin 5 mg.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_ace3a203","claim_text":"Adams KK, et al. Re-evaluating aztreonam and ceftazidime hypersensitivity: fraternal not identical twins","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_51177570","claim_text":"Baldolli A, et al. Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_50e70774","claim_text":"Furuya-Kanamori L, et al. Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: A systematic review and network meta-analysis","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_8c485c43","claim_text":"Lin DS, et al. Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_8d4c5938","claim_text":"Petrelli F, et al. Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_9ab55ed1","claim_text":"Forty-five out of 71 subjects in the sitagliptin group and 41 out of 62 subjects in the conventional group filled out the QOL questionnaire at week 104.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_f6740719","claim_text":"The DTR-QOL7 score at week 104 was significantly increased from baseline in the sitagliptin group, while that in the conventional group was not changed.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_76c3e5aa","claim_text":"Change in HbA1c was negatively associated with change in score.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_3b12dd67","claim_text":"The study population consisted of 71 subjects in the sitagliptin group and 62 subjects in the conventional group who were treated with insulin.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_7da1fbb6","claim_text":"ClinicalTrialRegistration: UMIN000007396 and Funding: Mitsubishi Tanabe Pharma Co., Ono Pharmaceutical Co., and Novo Nordisk.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_96bc8461","claim_text":"The combination of GLP-1 RAs, SGLT-2i, and DPP-4i can significantly reduce HbA1c levels.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_c85e0654","claim_text":"The combination of GLP-1 RAs, SGLT-2i, and DPP-4i can significantly reduce fasting plasma glucose levels.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_3e347b20","claim_text":"The combination of GLP-1 RAs can significantly reduce body weight in Type 2 diabetes mellitus patients.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_2cd7c237","claim_text":"The dose of basic insulin is reduced after the combination use of GLP-1 RAs.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_92ac3fa2","claim_text":"GLP-1 RAs increase the risk of hypoglycemia compared to placebo.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_7836aecf","claim_text":"A study evaluated the clinical and metabolic profile in a type 1 diabetes cohort.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_cabb91de","claim_text":"The study included 20 type 1 Diabetes subjects above 18 years of age with poorly controlled glycemia (HbA1c 7 to 10%).","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_3d7dae6d","claim_text":"The study used sitagliptin and dapagliflozin as adjuvant therapies in combination with insulin.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_2eceb7fc","claim_text":"Sitagliptin did not reduce fasting plasma glucagon levels when added to dapagliflozin.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0},
{"id":"c_0d57aea8","claim_text":"Dapagliflozin increased the median ketone (beta-hydroxybutyrate) levels compared to baseline.","claim_type":"fact","supporting_count":0,"refuting_count":0,"neutral_count":0}]
